300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Italy
Belize
Algeria
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Finland
Mongolia
Belarus
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Cascara Ventures, VC Fund

Cascara Ventures

VC Fund

Brussels, Belgium

Cascara Ventures is a VC fund in Brussels focused on Health Care and Biotechnology. Cascara Ventures is the new investment fund of Adriaan Hart de Ruijter, experienced entrepreneur and investor in life sciences. Founded in 2016, Cascara invests in the seed stage of companies that apply technology to prevention, therapy and research. Examples are vaccines, medical devices, pharmaceuticals, imaging, software, medical data, robotics,healthcare services, diagnostics and cell therapy.

Total investments:
13
Last investment:
Lead investor:
8%

Last updated:

Industries Cascara Ventures invests in

Health CareBiotechnologyMedical DeviceMedicalWearables

Stages Cascara Ventures invests in

Series ASeedSeries BSeries CVenture - Series Unknown

Countries Cascara Ventures invests in

GermanyFinlandThe Netherlands

Round sizes

Series A $2M–$7.9M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2M–$7.9M

Investment Focus

Industry

  • Health Care 5 (38%)
  • Biotechnology 5 (38%)
  • Medical Device 5 (38%)
  • Medical 4 (31%)
  • Wearables 2 (15%)
See all 19 industries →

Stage

  • Series A 6 (46%)
  • Seed 3 (23%)
  • Series B 2 (15%)
  • Series C 1 (8%)
  • Venture - Series Unknown 1 (8%)

Country

  • Germany 6 (46%)
  • Finland 2 (15%)
  • The Netherlands 1 (8%)

Team

NameTitleInvestmentsLinksEmail
Adriaan Hart de Ruijter
Adriaan Hart de Ruijter Managing Director
Managing Director Total investments: 10
Find email

Investments

CompanyDescriptionRoundLinks
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). $7.9M / Series A / May 27, 2025
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. $2.1M / Venture - Series Unknown / Dec 14, 2021
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). $1.2M / Seed / Oct 25, 2017
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. Series A / Jul 17, 2017
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivityreaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society. $2M / Series A / Jan 23, 2017
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. Series A / Jun 16, 2016
xbird is a provider of software solutions in the healthcare sector, founded in Berlin in 2015. The company uses artificial intelligence to personalize therapies for better results. Especially in diabetes therapy, the algorithms developed by xbird can record the behavior and lifestyle of patients using smartphones and other wearables. In this way,as part of holistic care, health risks can be identified and prevented and long-term treatment can be optimized. Seed / Jan 01, 2016
Preventicus engineers products for smartphones and smartwatches that obtain health parameters without any extra accessories. It generates data conclusive to a degree previously only obtainable by physicians. Preventicus’ software applications are certified medical devices with an accuracy verified in clinical studies. Its primary product is a classI medical device. Preventicus is the creator of Preventicus Heartbeats, a smart screening solution that identifies atrial fibrillation for stroke prevention, based on technologies that are present in a standard smartphone or smartwatch.Preventicus was founded in 2014 by Thomas Hübner. It is based in Jena, Germany. Series A / Jan 01, 2016
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation. Series C
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. Seed
See all 13 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Italy
Belize
Algeria
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Finland
Mongolia
Belarus
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Cascara Ventures invest in?

Cascara Ventures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Cascara Ventures's check size?

Cascara Ventures typically joins rounds of $2M–$7.9M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cascara Ventures participates in.

How do I contact Cascara Ventures?

Public channels for Cascara Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Cascara Ventures?

The team at Cascara Ventures includes Adriaan Hart de Ruijter (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Cascara Ventures Cascara Ventures Find emails